Global Vaccine Market Outlook 2020 - SBD...

All rights reserved. This publication is protected by copyright. No part of it may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic mechanical, photocopying, recording or otherwise without the prior written permission of the publisher.

published: May’ 2014

Global Vaccine Market Outlook 2020

TABLE OF CONTENTS

4.1 Pneumococcal4.2 Influenza4.3 Cancer4.4 Polio4.5 Varicella4.6 Rotavirus4.7 Meningococcal4.8 DTP4.9 Hepatitis4.10 Measles, Mumps, and Rubella (MMR)4.11 Japanese Encephalitis4.12 Tuberculosis4.13 Malaria4.14 Rabies4.15 Typhoid4.16 HIV

5.1 US5.2 Europe5.3 Japan5.4 China5.5 India5.6 Brazil

1. Analyst View

2. Research Methodology

3. Global Vaccine Market Outlook to 2020

4. Major Vaccines: Current and Future Market Analysis


5. Key Geographical Markets

6. Pipeline Analysis

TABLE OF CONTENTS

7.1 GSK 7.1.1 Business Overview 7.1.2 Vaccine Portfolio & Pipeline 7.1.3 Strengths and Weaknesses7.2 Sanofi-Pasteur 7.2.1 Business Overview 7.2.2 Vaccine Portfolio & Pipeline 7.2.3 Strengths and Weaknesses7.3 Pfizer 7.3.1 Business Overview 7.3.2 Vaccine Portfolio & Pipeline 7.3.3 Strengths and Weaknesses7.4 Merck 7.4.1 Business Overview 7.4.2 Vaccine Portfolio & Pipeline 7.4.3 Strengths and Weaknesses7.5 Novartis 7.5.1 Business Overview 7.5.2 Vaccine Portfolio & Pipeline 7.5.3 Strengths and Weaknesses7.6 Emergent Biosolutions 7.6.1 Business Overview 7.6.2 Vaccine Portfolio & Pipeline 7.6.3 Strengths and Weaknesses7.7 AstraZeneca Plc. 7.7.1 Business Overview 7.7.2 Vaccine Portfolio & Pipeline 7.7.3 Strengths and Weaknesses7.8 Baxter International Inc. 7.8.1 Business Overview 7.8.2 Vaccine Portfolio & Pipeline 7.8.3 Strengths and Weaknesses7.9 BioCSL (CSL Biotherapies) 7.9.1 Business Overview 7.9.2 Vaccine Portfolio & Pipeline 7.9.3 Strengths and Weaknesses7.10 Dendreon Corporation 7.10.1 Business Overview 7.10.2 Vaccine Portfolio & Pipeline 7.10.3 Strengths and Weaknesses7.11 Takeda Pharmaceutical Company Limited 7.11.1 Business Overview 7.11.2 Vaccine Portfolio & Pipeline 7.11.3 Strengths and Weaknesses7.12 Crucell 7.12.1 Business Overview 7.12.2 Vaccine Portfolio & Pipeline 7.12.3 Strengths and Weaknesses

7. Competitive Landscape


LIST OF FIGURES

Figure 3-1: Global - Vaccine Market (Billion US$), 2013-2020Figure 4-1: Global - Causes of Deaths in Children (<5 Years) among Low-income Countries (%), 2011Figure 4-2: Global - Pneumococcal Vaccine Market (Billion US$), 2013-2020Figure 4-3: Global - Influenza Vaccine Market (Billion US$), 2013-2020Figure 4-4: Global - Cancer Vaccine Market (Billion US$), 2013-2020Figure 4-5: Global - Polio Vaccine Market (Billion US$), 2013-2020Figure 4-6: Global - Varicella Vaccine Market (Billion US$), 2013-2020Figure 4-7: Global - Rotavirus Vaccine Market (Billion US$), 2013-2020Figure 4-8: Global - Meningococcal Vaccine Market (Billion US$), 2013-2020Figure 4-9: Global - Number of Diphtheria Incidences by Region (2009 & 2010)Figure 4-10: Global - Number of nTetanus Incidences by Region (2009 & 2010)Figure 4-11: Global - Number of tTetanus Incidences by Region (2009 & 2010)Figure 4-12: Global - Number of Pertussis Incidences by Region (2009 & 2010)Figure 4-13: Global - DTP Vaccine Market (Billion US$), 2013-2020Figure 4-14: Global - Hepatitis Vaccine Market (Billion US$), 2013-2020Figure 4-15: Global - Number of Measles Incidences by Region (2009 & 2010)Figure 4-16: Global - Number of Mumps Incidences by Region (‘000), 2009 & 2010Figure 4-17: Global - Number of Rubella Incidences by Region (2009 & 2010)Figure 4-18: Global - MMR Vaccine Market (Million US$), 2013-2020Figure 4-19: Global - Japanese Encephalitis Market (Million US$), 2013-2020Figure 4-20: Global - Sources for Funding in HIV Vaccine R&D (%), 2011Figure 5-1: Global - Vaccine Market by Region (%), 2013Figure 5-2: Global - Vaccine Market by Region (%), 2020Figure 5-3: US - Vaccine Market (Billion US$), 2013-2020Figure 5-4: Europe - Vaccine Market (Billion US$), 2013-2020Figure 5-5: Japan - Vaccine Market (Billion US$), 2013-2020Figure 5-6: China - Vaccine Market (Billion US$), 2013-2020Figure 5-7: India - Share of Domestic Consumption and Exports in Vaccine Market (2013)Figure 5-8: India - Vaccine Market (Billion US$), 2013-2020Figure 5-9: Brazil - Vaccine Market (Billion US$), 2013-2020Figure 7-1: Global - Share of Key Players in Vaccine Market (2013)Figure 7-2: GSK - Revenue Breakup by Business Segment (%), 2013Figure 7-3: GSK - Vaccine Revenue Breakup by Product (%), 2013Figure 7-4: Sanofi-Pasteur - Revenue Breakup by Business Segment (%), 2013Figure 7-5: Sanofi-Pasteur - Vaccine Revenue Breakup by Product (%), 2013Figure 7-6: Pfizer - Revenue Breakup by Business Segment (%), 2013Figure 7-7: Pfizer - Revenue Breakup by Biopharmaceuticals (%), 2013Figure 7-8: Merck - Revenue Breakup by Business Segment (%), 2013Figure 7-9: Merck - Pharmaceutical Division Revenue by Segment (%), 2013Figure 7-10: Novartis - Revenue Breakup by Business Segment (%), 2013Figure 7-11: AstraZeneca - Revenue Breakup by Therapy Area (%), 2013Figure 7-12: Baxter International - Revenue Breakup by Business Segment (%), 2013Figure 7-13: BioCSL - Revenue Breakup by Business Segment (%), 2013Figure 7-14: Takeda Pharmaceutical - Revenue Breakup by Business Segment (%), 2013Figure 7-15: Crucell - Revenue Breakup by Vaccine Type (%), 2010


LIST OF TABLES

Table 4-1: Pneumococcal Vaccine Market - Key Players and VaccinesTable 4-2: Key Pneumococcal Vaccines in PipelineTable 4-3: Influenza Vaccine Market - Key Players and VaccinesTable 4-4: Key Influenza Vaccines in PipelineTable 4-5: Global - Cancer Statistics in More Developed and Less Developed Regions (2008)Table 4-6: Cancer Vaccine Market - Key Players and VaccinesTable 4-7: Key Cancer Vaccines in PipelineTable 4-8: Polio Vaccine Market - Key Players and VaccinesTable 4-9: Key Polio Vaccines in PipelineTable 4-10: Varicella Vaccine Market - Key Players and VaccinesTable 4-11: Rotavirus Vaccine Market - Key Players and VaccinesTable 4-12: Key Rotavirus Vaccines in PipelineTable 4-13: Meningococcal Vaccine Market - Key Players and VaccinesTable 4-14: Key Meningococcal Vaccines in PipelineTable 4-15: DTP Vaccine Market - Key Players and VaccinesTable 4-16: Key DTP Vaccines in PipelineTable 4-17: Hepatitis Vaccine Market - Key Players and VaccinesTable 4-18: Key Hepatitis Vaccines in PipelineTable 4-19: MMR Vaccine Market - Key Players and VaccinesTable 4-20: Key MMR Vaccines in PipelineTable 4-21: Japanese Encephalitis Vaccine Market - Key Players and VaccinesTable 4-22: Key Japanese Encephalitis Vaccines in PipelineTable 4-23: Tuberculosis Vaccine Market - Key Players and VaccinesTable 4-24: Key Tuberculosis Vaccines in PipelineTable 4-25: Key Malaria Vaccines in PipelineTable 4-26: Rabies Vaccine Market - Key Players and VaccinesTable 4-27: Key Rabies Vaccines in PipelineTable 4-28: Typhoid Vaccine Market - Key Players and VaccinesTable 4-29: Key Typhoid Vaccines in PipelineTable 4-30: Global - Number of HIV/AIDS Patients by Region (2009)Table 4-31: Key HIV Vaccines in PipelineTable 5-1: China - Vaccine ClassificationTable 6-1: Vaccine Pipeline AnalysisTable 7-1: GSK - Vaccines PortfolioTable 7-2: GSK - Vaccines in PipelineTable 7-3: GSK - Strengths and WeaknessesTable 7-4: Sanofi-Pasteur - Vaccines PortfolioTable 7-5: Sanofi-Pasteur - Vaccines in PipelineTable 7-6: Sanofi-Pasteur - Strengths and WeaknessesTable 7-7: Pfizer - Vaccines PortfolioTable 7-8: Pfizer - Vaccines in PipelineTable 7-9: Pfizer - Strengths and WeaknessesTable 7-10: Merck - Vaccines PortfolioTable 7-11: Merck - Vaccines in PipelineTable 7-12: Merck - Strengths and WeaknessesTable 7-13: Novartis - Vaccines PortfolioTable 7-14: Novartis - Vaccines in Pipeline


LIST OF TABLES

Table 7-15: Novartis - Strengths and WeaknessesTable 7-16: Emergent Biosolutions - Vaccines PortfolioTable 7-17: Emergent Biosolutions - Vaccines in PipelineTable 7-18: Emergent Biosolutions - Strengths and WeaknessesTable 7-19: AstraZeneca - Vaccines PortfolioTable 7-20: AstraZeneca - Vaccines in PipelineTable 7-21: AstraZeneca - Strengths and WeaknessesTable 7-22: Baxter International - Vaccines PortfolioTable 7-23: Baxter International - Vaccines in PipelineTable 7-24: Baxter International - Strengths and WeaknessesTable 7-25: BioCSL - Vaccines PortfolioTable 7-26: BioCSL - Strengths and WeaknessesTable 7-27: Dendreon Corporation - Vaccines PortfolioTable 7-28: Dendreon Corporation - Vaccines in PipelineTable 7-29: Dendreon Corporation - Strengths and WeaknessesTable 7-30: Takeda Pharmaceutical - Vaccines PortfolioTable 7-31: Takeda Pharmaceutical - Vaccines in PipelineTable 7-32: Takeda Pharmaceutical - Strengths and WeaknessesTable 7-33: Crucell - Vaccines PortfolioTable 7-34: Crucell - Vaccines in PipelineTable 7-35: Crucell - Strengths and Weaknesses



Japanese Encephalitis

Sample Sections from the Report

Japanese Encephalitis (JE) is a significant cause of human morbidity and mortality throughout Asia. Approximately, xx% of the world’s population lives in regions endemic with Japanese encephalitis. An estimated xx cases and x–x deaths occur annually due to this disease, globally. It could be fatal for one in five infected people. Half of all the infected people may have long-term neurological symptoms .

The disease is endemic with seasonal distribution in parts of China, the Russian Federation’s south-east, South Asia and Southeast Asia. All year, transmission is observed in tropical climate zones. Currently, JE is con-sidered hyperendemic in northern India and southern Nepal as well as in parts of central and southern India, and authorities have responded with immunization campaigns. The spread of JE in new areas has been cor-related with agricultural development and intensive rice cultivation supported by irrigation programs.

JE vaccines have been available since decades, and have proved their potential to control the disease. WHO recommends JE immunization in all regions where the disease is a recognized public health problem. However, until recently, the use of vaccine has been limited due to vaccine price, cumbersome immunization schedules, and lack of recognition of the burden of disease.

The only big pharma player dominant in the market is Novartis, whose prophylactic vaccine against JE was ap-

proved in the US, Europe, Canada, Hong Kong, Singa-pore and Israel, under the trade name Ixiaro as well as in Australia and New Zealand (marketed as Jespect).

Ixiaro is indicated for active immunization against Japa-nese Encephalitis in adults, adolescents, children and infants aged x months and older in EU member states, Norway, Liechtenstein and Iceland. In all other licensed territories, Ixiaro/Jespect is indicated for use in persons x years of age and above (x years and above in the US). Besides, Ixiaro, over the past years, live attenuated SA14-14-2 vaccine manufactured in China, has become a widely used vaccine in endemic countries, which re-quires only one dose for primary immunization.

S. No. Company Vaccine

1 Novartis Ixiaro

2 Chengdu Institute of Biological Products SA14-14-2 Vaccine

Table 4-21: Japanese Encephalitis Vaccine Market - Key Players and Vaccines

Source: RNCOS

The spread of JE in new areas has been correlated with agri-

cultural development and inten-sive rice cultivation supported

by irrigation programs.


The market for JE Vaccine is expected to reach around US$ x Billion by 2020, growing at a CAGR of around x% during 2013-2020. This growth will be largely driven by expanding markets in regions of North America, EU, Australia, New Zealand, India and Japan.

Recently, India has launched its first indigenous vac-cine to protect children from Japanese Encephalitis.

Till now the country has been importing vaccine from China. JENVAC, the Vero cell derived purified inactivated JE vaccine has received marketing authorizations from DGCI through public private partnership between Indian Council of Medical Research and Bharat Biotech.

Meanwhile, Sanofi-Pasteur has launched its JE vaccine in Australia and Thailand in 2012 for individuals aged xx months and over. Thereafter, the vaccine was launched in Malaysia and Philippines in 2013. The extension of

the indication to include children aged nine months and older has been submitted and is currently under ap-proval in Asia Pacific region.

2013e 2014f 2015f 2016f 2017f 2018f 2019f 2020f

Figure 4-19: Global - Japanese Encephalitis Market (Million US$), 2013-2020

Source: RNCOS

S. No. Company Vaccine Phase

1 Sanofi-Pasteur Imojev III

Table 4-22: Key Japanese Encephalitis Vaccines in Pipeline

Source: RNCOS


1 Merck Dr.Whitehouse Station, NJ 08889-0100,United StatesPhone: 908-423-1000Fax: 908-735-1253Website: www.merck.com

Established in 1891, Merck & Co. delivers innovative solutions by providing vaccines, biological therapies, prescription medicines, animal health and consumer care products. The company has operations in around four major divisions - Pharmaceutical, Animal Health, Consumer Care and Alliances segment.

The company operates through subsidiaries outside United States. Merck has expanded its operations in countries located in Latin America, the Middle East, Africa, Eastern Europe, and Asia Pacific.

The Pharmaceutical segment involves the marketing of

human health pharmaceutical and vaccine products. Human health pharmaceutical consists of therapeutic and preventive medicines for the treatment of human disorders. Vaccine products consist of adult, pediatric, adolescent vaccines.

Animal Health division discovers, develops, manufac-tures and markets animal health products including vaccines.

Consumer Care division develops consumer care prod-ucts, including over-the-counter, foot care and sun care products.

Merck

Business Overview

Figure 7-8: Merck - Revenue Breakup by Business Segment (%), 2013

Figure 7-9: Merck - Pharmaceutical Division Revenue by Segment (%), 2013

Source: xx

Pharmaceutical DrugsAnimal Health Vaccines

Consumer Care OthersSource: xx


Merck has a diverse vaccines portfolio. Its highest selling vaccine is Gardasil, sales of which grew xx% in 2013 to US$ xx Billion, driven by increased vaccination in males aging x to x years in the United States, launch of the vaccine in Japan, and growth in emerging markets.

Another of its blockbuster vaccines is ProQuad/M-M-R II/Varivax clocked in US$ xx Billion in sales in 2013, an increase of xx% compared to previous year.

Vaccine Portfolio & Pipeline

S. No. Vaccine Indication

1 Afluria Influenza

2 BCG Tuberculosis

3 Comvax Haemophilus influenzae type B infection, Hepatitis B

4 Gardasil Human papillomavirus type 6, 11, 16, 18 infection

5 M-M-R II Measles, Mumps, Rubella

6 Pedvax HIB Haemophilus influenzae type B infection, Meningitis

7 Pneumovax 23 Pneumonia

8 ProQuad Measles, Mumps, Rubella, Varicella

9 Recombivax HB Hepatitis B

10 RotaTeq Rotavirus infection

11 Tetanus, Diphtheria Toxoids Tetanus, Diphtheria

12 Vaqta Hepatitis A

13 Varivax Varicella

14 Zostavax Herpes zoster

15 TICE BCG Treatment and prophylaxis of carcinoma in situ of the urinary bladder and for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection.

Table 7-10: Merck - Vaccines Portfolio

Source: xx


The company has some very strong vaccine candidates in pipeline. Its V503 is a nine-valent HPV vaccine in development to help protect against certain HPV-related diseases. V503 incorporates antigens against five ad-ditional cancer-causing HPV types as compared with Gardasil.

Moreover, it’s another important vaccines is V419, which is an investigational hexavalent pediatric com-

bination vaccine, that contains components of current Merck vaccines, designed to help protect against six po-tentially serious diseases: diphtheria, tetanus, whooping cough (Bordetella pertussis), polio (poliovirus types 1, 2, and 3), invasive disease caused by Haemophilus influ-enzae type b, and hepatitis B that is being developed in collaboration with Sanofi-Pasteur-Merck. The company anticipates filing a BLA for V419 with the FDA in 2014.

Table 7-10: Merck - Vaccines Portfolio

Source: xx

S. No. Vaccine Indication Phase

1 V212 Herpes Zoster III

2 V419 Diphtheria, Tetanus, Whooping Cough (Bordetella Pertussis), Polio (Polio Types 1, 2, And 3), Invasive Disease Caused By Haemophilus Influenzae Type B, And Hepatitis B.

III

3 V114 Pneumococcal Infections II

4 V503 HPV-Related Cancers Under review


Research Methodology

Our dedicated team of industry experts intensively monitored and analyzed the healthcare industry scenario of almost all major economies in the world. The team found that due to rising healthcare cost and increasing prevalence of various severe diseases, the consumer behavior has changed drastically. Now, consumers prefer vaccines as preven-tive measures rather than relying upon treatments. This has boosted the demand of vaccines in the world, resulting in a generation of greater profits for vaccine players. This led us to study the global vaccine industry and explore various growth opportunities in the market.

For our study, we gathered information from various credible sources, such as company websites, business articles, health authorities, various creditable domestic news sources, and some of our paid databases, such as LexisNexis, EIU, and many others. Our team of experts has prudently evaluated all the collected information and presented it in a chronological order to depict a meaningful and clear picture of the global vaccine industry. This is worthy to mention here that while compiling the data, we have cross-checked all the information gathered from other multiple sources and data warehouses, so that we can present the most accurate and precise information on the industry.

We have well identified and analyzed all the emerging trends, important industry drivers, and key challenges that the industry is facing up to. Along with this, we have also discovered the possible growth areas in terms of geographical expansion, technological developments, and many others. With the co-ordination of all the factors, we have been suc-cessful in presenting a coherent analysis of the performance of the concerned industry.

Finally, the report also presents future forecasts for the industry. The forecast provided is based on the result of our economic and judgmental analysis and past drivers, challenges, and opportunities for expansion. While forecasting, we have given due consideration to the current industry trends. In this way, our report depicts the most unbiased picture of the global vaccine market.


License Type

Payment Options

Electronic Access - Single User License : US$ 1500.00

CD-ROM Mail Delivery - Single User License : US$ 1700.00

Hard Copy Mail Delivery - Single User License : US$ 1700.00

Electronic Access - Multi-User License - Single User License : US$ 2000.00

Pay by Credit Card

Pay by wire transfer

All payments made using your credit card are processed by our Payment Gateway www.2checkout.com. On receipt of con-firmation that your payment has been credited to our account (generally takes 4 to 6 hours) we shall dispatch the electronic copy of the report to you.

This allows you to transfer money from your bank account to our account. Please allow 3-4 working days for processing of this order.

Contact Information

B 129, Sector 6, Noida, IndiaPh.: + 91 (120) 4224700 Extn.

203/208Fax: + 91 (120) 4224707

Email: [email protected]: www.rncos.com

Bank Wire Transfer Details

Account Name : RNCOS E Services Private Limited Account No. : 1302125Bank Name : The Ratnakar Bank Limited, IndiaBank Address : P-7, Sector - 18, Noida, UP-201301. SWIFT CODE : RATNINBBXXX

Correspondent Bank Details Name of the Bank : Wells Fargo Bank NA., NEW YORK, USAAccount Number : 2000191007114 Swift Code : PNBPUS3NNYC


Established in 2002, RNCOS is a premier source of healthcare research and information provider. We bring first-hand informa-tion and prudent analysis on the healthcare industry, technologies, economic and non-economic market parameters, poten-tial markets, and key competitors, to help clients identify prospective growth areas and gain competitive edge.

All our research solutions are supported by robust, evidence-based analytics grounded by extensive primary and secondary research. They not only provide the most up-to-date market figures, forecasts, and pipeline data, but offers valuable insights on successes and failures in the ever-competitive healthcare industry.

Our reports provide strategic information for investment bankers, companies, management consultants, trade associations, corporate executives and business analysts. Our work helps them to support critical business decisions such as, entering new markets, launching and enhancing products, making acquisitions or strategic investments, unseating competitors and more.

About RNCOS

WORK PROCESS

The findings, conclusions and recommendations that RNCOS delivers are based on information gathered in good faith from both primary and secondary sources. Neither the company nor any of its employees makes any warranty, express or implied, including the warranties of merchantability and fitness for a particular purpose, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights.

No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, elec-tronic, mechanical, photocopying, recording or otherwise, without the prior permission of RNCOS. Such protected material, however, may be used under the terms of “fair use” as defined in the copyright laws, which generally permits use for non-commercial educational purposes such as teaching, research, criticism, and news reporting.

Unless otherwise stated, the copyright, database rights, and other similar rights of this publication are solely owned by RN-COS.

You are permitted to print or download extracts from this material for your personal use only. None of this material may be used for any commercial or public use.

No part of research material appearing may be reproduced, stored in or transmitted on any other Website without written permission of RNCOS and any payments of a specified fee. Requests to republish any material may be sent to us and it is our sole discretion to allow it or not.

Disclaimer

Global Vaccine Market Outlook 2020 - SBD...

Documents

Transcript of Global Vaccine Market Outlook 2020 - SBD...